Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 24

Inclusion Criteria

Male and female subjects between 18 and 60 years of age inclusive
A Body Mass Index (BMI) between 18 and 29 kg/m2
Signed informed consent prior to trial participation
Ability to swallow multiple capsules without difficulty
Ability to ingest a standard high-fat test meal
Acceptable laboratory values that indicated adequate baseline organ function were required at the time of screening. Laboratory values were considered to be acceptable if severity was less than or equal to Grade 1, based on the AIDS Clinical Trials Group (ACTG) Grading Scale
Acceptable medical history, physical examination and 12-lead ECG were required prior to entering the treatment phase of the study
Willingness to abstain from alcohol for 48 hours prior to study Day 0 and abstain from alcohol for the duration of the study. In addition, ingestion of red wine is not allowed within 5 days prior to Day 0 (Visit 2)
Willingness to abstain from grapefruit or grapefruit juice or products containing grapefruit juice starting 10 days prior to any administration of study drug up until the end of the study
Willingness to abstain from ingestion of Seville oranges, garlic supplements, St. John's Wort, or Milk Thistle, within 5 days of treatment and for the duration of the study
Willingness to abstain from methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.) within 48 hours of each pharmacokinetic sampling day and until after the last sample from each of the intensive sampling days was collected
Willingness to abstain from over the counter herbal medications for the duration of the study
Willingness to abstain from vigorous physical exercise during intensive pharmacokinetic days
Reasonable probability for completion of the study
Non-smokers for at least 3 months prior to Day 0

Exclusion Criteria

Female subjects who are of reproductive potential and who:
1. Have positive serum β-hCG at Visit 1, or on Day 0
2. Are not using a barrier contraceptive method for at least 3 months prior to Visit 2 (Day 0)
3. Are not willing to use a reliable method of barrier contraception (such as diaphragm or condoms), during the trial and for 30 days after trial completion/termination
4. Are breast-feeding
Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to study initiation and for the duration of the study
Use of hormone replacement therapy within 1 month prior to study initiation and for the duration of the study
Participation in another trial with an investigational medicine within 60 days prior to Day 0 (Visit 2)
Use of any prohibited medication listed in the protocol within 30 days prior to Day 0 (Visit 2)
Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the trial
History of acute illness within 60 days of trial initiation. Subjects are excluded for these disorders greater than 60 days if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
Serological evidence of hepatitis B (HBV) or hepatitis C (HCV)
Serological evidence of exposure to HIV
Recent history of alcohol or substance abuse (within 6 months of study period)
Blood or plasma donations within 30 days prior to Day 0 (Visit 2) or during the trial
Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg
Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir (TPV), ritonavir (RTV) or clarithromycin (CLR) to the subject
Subjects who have taken, within 7 days prior to Day 0 (Visit 2), any over-the-counter or prescription drugs that, in the opinion of the investigator in consultation with the BI clinical monitor, might interfere with either the absorption, distribution or metabolism of the test substances
Known hypersensitivity to TPV, RTV, sulfonamides, or CLR
Lactose intolerance or intolerance to high-fat foods
Allergies or intolerance to foods such as soybean, wheat, milk, eggs or gluten
Inability to adhere to requirements of the protocol

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Sequential administration	High-Fat Test Meal	-
Sequential administration	Ritonavir	-
Sequential administration	Tipranavir	-
Sequential administration	Clarithromycin	-

Primary Outcome Measures

Name	Time	Method
Area under plasma concentration time curve from 0-12 hours (AUC0-12h)	up to 12 hours
Maximum plasma concentration (Cmax)	up to 12 hours
Plasma trough concentration (Cp12h)	up to 12 hours

Secondary Outcome Measures

Name	Time	Method
Oral clearance (CL/F)	up to 12 hours
Volume of distribution (V)	up to 12 hours
Apparent terminal half life (t1/2)	up to 12 hours
Time of maximum concentration (Tmax)	up to 12 hours
Mean Residency Time (MRT)	up to 12 hours
Number of patients with adverse events	up to day 13
Number of patients with clinically significant laboratory findings	up to day 13

Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

Recruitment & Eligibility

Study & Design

Instant Trial Alerts

Instant Trial Alerts